The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma.
Mrinal M. Gounder
No relevant relationships to disclose
Mark Andrew Dickson
No relevant relationships to disclose
Nian Wu
No relevant relationships to disclose
S. Percy Ivy
No relevant relationships to disclose
Richard D. Carvajal
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Mary Louise Keohan
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Joseph Patrick Erinjeri
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Lanier Tanner
No relevant relationships to disclose
Rita Morales
No relevant relationships to disclose
Mercedes M Condy
No relevant relationships to disclose
Yelena Ustoyev
No relevant relationships to disclose
Robert G. Maki
Research Funding - Roche Instituitional Research Grant
William D. Tap
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose